Caris Life Sciences (CAI) Gross Profit (2024 - 2026)

Caris Life Sciences' Gross Profit history runs 3 years deep, the most recent figure standing at $214.2 million for Q1 2026.

• In Q1 2026, Gross Profit rose 256.93% year-over-year to $214.2 million; the TTM figure through Mar 2026 stood at $518.4 million (up 56.87% YoY), while the FY2025 annual figure was $549.7 million, up 36.78% from the prior year.
• Gross Profit for Q1 2026 stood at $214.2 million, up from $38.2 million in the prior quarter.
• The five-year high for Gross Profit was $214.2 million in Q1 2026, with the low at $38.2 million in Q4 2025.
• The 3-year median for Gross Profit is $106.5 million (2024), against an average of $106.1 million.
• The sharpest annual moves came in 2025 and 2026: Gross Profit slumped 69.81% in 2025, then jumped 256.93% in 2026.
• Caris Life Sciences' Gross Profit stood at $126.6 million in 2024, then plunged by 69.81% to $38.2 million in 2025, then surged by 460.36% to $214.2 million in 2026.
• Business Quant data shows CAI's Gross Profit at $214.2 million in Q1 2026, $38.2 million in Q4 2025, and $149.9 million in Q3 2025.